Findings from the international FORT-2 clinical trial showed that a combination treatment including immunotherapy is safe and ...

Findings from the international FORT-2 clinical trial showed that a combination treatment including immunotherapy is safe and tolerable in patients ...

Undetectable pre-cystectomy ctDNA predicts better pathological outcomes post-radical cystectomy Patients with undetectable pre-cystectomy status demonstrated recurrence-free survival, regardless of ...

In vivo, using the subcutaneous MB49 bladder cancer model, HSV5-15 virus expressing both the cytokine and TLR agonist ...

In urothelial bladder cancer, increased T cell infiltration has been correlated with longer patient survival. Previous clinical studies with an FGFR inhibitor, rogaratinib, demonstrated that the ...

Trodelvy in locally advanced or metastatic urothelial cancer may provide another option for those whose disease progressed ...

Among patients with high-risk muscle-invasive urothelial carcinoma, postsurgical Keytruda extended the time some lived ...

Researchers compared health-related quality of life with nivolumab added to first-line chemo vs chemo alone in patients with ...

Enfortumab vedotin showed a robust disease control rate in patients with urothelial cancer outside of a clinical trial, and ...

Opens in a new tab or window In the U.S., the economic burden associated with the latest first-line treatments for locally advanced or metastatic urothelial carcinoma (la/mUC) is significant.

In addition, the proportion of muscle-invasive bladder cancer was limited and ... value in locally advanced invasive or metastatic urothelial cancer.